RNA与DNA Sanger测序对比下一代测序检测初治HIV-1耐药突变
该研究纳入48例未接受抗逆转录病毒治疗的HIV-1感染者,比较RNA Sanger测序、DNA Sanger测序与RNA下一代测序(NGS)在逆转录酶、蛋白酶和整合酶基因中检测耐药相关突变的效能。结果显示DNA Sanger测序较RNA Sanger测序未明显提高耐药突变检出,NGS可检出更多少数耐药突变,但其临床相关性有待进一步研究。
要点
- DNA Sanger测序较RNA Sanger测序未明显改善初治患者耐药突变检出。
- NGS可检出更多少数耐药突变,但短期治疗结局未见影响。
- 三种方法在整合酶基因中均未检出主要耐药突变。
核心结论
- DNA Sanger测序较RNA Sanger测序未明显提高初治患者耐药相关突变检出。
- NGS可检出额外少数耐药突变,但其临床相关性需进一步研究。
研究设计与样本
- 研究纳入48例未接受抗逆转录病毒治疗的HIV-1感染者。
- 对HIV-1逆转录酶、蛋白酶和整合酶基因进行比较。
- RNA与DNA Sanger测序按法国艾滋病研究机构(ANRS)推荐进行。
- RNA NGS使用HIV-1 Drug Resistance Assay v.3.0(Roche)在454 GS Junior测序仪上完成。
- 使用IAS-USA列表识别耐药相关突变,采用ANRS、Rega和Stanford算法解读耐药。
主要发现
- 使用RNA Sanger测序、DNA Sanger测序、NGS 20%阈值和NGS 5%阈值时,携带至少一个主要耐药突变的患者数分别为3、3、4和8例。
- 患者中检出大量次要突变,尤其在前列酶基因。
- 所有方法在整合酶基因中均未检出主要突变。
- RNA Sanger测序与DNA Sanger测序总体突变检出率相似,NGS 20%阈值检出率更高。
- 不同算法间存在耐药解读差异,NGS检出的少数耐药突变对短期治疗结局未见影响。
关键数值与推荐
- Sanger测序无法检出患病率低于约20%的耐药相关突变。
- 主要耐药突变患者数:RNA Sanger测序3例,DNA Sanger测序3例,NGS 20%阈值4例,NGS 5%阈值8例。
临床怎么用
- 初治HIV-1患者耐药检测中,DNA Sanger测序较RNA Sanger测序未显示明确优势。
- NGS可检出更多少数耐药突变,但当前其临床意义尚不明确,需结合进一步研究解读。
局限性
- NGS检出的少数耐药突变临床相关性需进一步研究。
- 不同耐药解读算法间存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sanger sequencing of plasma RNA is the standard method for HIV-1 drug resistance testing in treatment-naive patients, but is limited by the non-detection of resistance-associated mutations (RAMs) with prevalence below approximately 20%. OBJECTIVES: We compared RNA and DNA Sanger sequencing (RSS and DSS) with RNA next-generation sequencing (NGS) for RAM detection in HIV-1 reverse transcriptase (RT), protease (PR) and integrase (IN) genes. METHODS: Sanger sequencing was performed on RNA and DNA, following the recommendations of the French Agency for AIDS Research (ANRS). NGS was performed on RNA using the HIV-1 Drug Resistance Assay, v. 3.0 (Roche) on the 454 GS Junior sequencer. The IAS-USA list was used to identify RAMs. ANRS, Rega and Stanford algorithms were used for drug resistance interpretation. RESULTS: The study included 48 ART-naive patients. The number of patients with at least one major RAM was 3, 3, 4 and 8 when using RSS, DSS, NGS 20% and NGS 5%, respectively. Numerous minor mutations were detected in patients, especially in the protease gene. None of the methods detected any major mutation in the integrase gene. Overall, the mutation detection rate was similar between RSS and DSS, and higher with NGS 20%. Differences in drug resistance interpretation were found between algorithms. No impact of the minority RAMs detected by NGS was found on the short-term treatment outcome. CONCLUSIONS: DSS does not clearly improve the detection of RAMs in ART-naive patients, as compared with RSS. NGS allows detection of additional minority RAMs; however, their clinical relevance requires further investigation.
引用
- Alidjinou EK, Deldalle J, Hallaert C, et al. RNA and DNA Sanger sequencing versus next-generation sequencing for HIV-1 drug resistance testing in treatment-naive patients. J Antimicrob Chemother. 2017. PMID: 29091197. doi:10.1093/jac/dkx232
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。